Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

Cytokine Signaling: Genes, Genomes and Drugs

Loading video...

264 Views  
   
Air date: Friday, October 14, 2016, 10:00:00 AM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 264, (131 Live, 133 On-demand)
Category: Philip S. Chen - Innovation & Technology Transfer
Runtime: 01:05:24
Description: Eleventh annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer

John J. O'Shea graduated Phi Beta Kappa from St. Lawrence University with a Bachelor of Science degree, and then gained a Doctor of Medicine degree from the University of Cincinnati. He carried out a residency in Internal Medicine at the State University of New York Upstate Medical University and did subspecialty training at the National Institute of Allergy and Infectious Diseases, NIH. Dr. O’Shea has made fundamental discoveries related to the basic mechanisms underlying cytokine signal transduction, molecules that are critical for the development and functioning of the immune system. He and his colleagues first cloned the human tyrosine kinase JAK3 and discovered its role in signaling by interleukin-2. These insights led to the discovery of JAK3 mutations as a cause of severe combined immunodeficiency. The demonstration of the role of Janus kinases in cytokine signaling led Dr. O’Shea and his colleagues to propose that targeting JAKs would represent a new class of immunomodulatory drugs. He was awarded a U.S. patent for his work on Janus family kinase inhibitors and developed a Cooperative Research and Development Agreement with the pharmaceutical company Pfizer, which generated one such compound. This drug, tofacitinib, is now approved for the treatment of rheumatoid arthritis and is the first oral therapy for rheumatoid arthritis approved in a decade.

Dr. O'Shea has received numerous awards, including: the NIH Director's Award four times, the US Public Health Service Physician Researcher of the Year Award, the Irish Immunology Public Lecture Award, the Arthritis Foundation's Howley Prize, the Ross Prize in Molecular Medicine, the Daniel Drake Prize, as well as Danny Thomas, Lockey, Cochrane, Talmadge and Stone lectureships. He was nominated to give a lecture at the Nobel Forum and was a Distinguished Lecturer at this year’s American Association of Immunology annual meeting. He was designated as one the “The World’s Most Influential Scientific Minds 2003-2014” by Thompson Reuters. Dr. O’Shea is a member of the American Association of Physicians, a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine. He has published more than 300 peer-reviewed articles and has been on the editorial boards of many journals including the Journal of Biological Chemistry, Blood, Journal of Immunology, Immunity and the Journal of Experimental Medicine. Dr. O’Shea is a founding Director of the NIH/Oxford Graduate Program in Biomedical Science and a Professor of Pathology at the University of Pennsylvania.
Debug: Show Debug
Author: John J. O'Shea, M.D., Scientific Director and Senior Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
Download: To download this event, select one of the available bitrates:
[64k]  [150k]  [240k]  [440k]  [740k]  [1040k]  [1240k]  [1440k]  [1840k]    How to download a Videocast
Caption Text: Download Caption File
CIT Live ID: 20026
Permanent link: https://videocast.nih.gov/launch.asp?19923